Amarin Corp Plcuk (AMRN) Cash from Operations (2010 - 2026)
Amarin Corp Plcuk (AMRN) reported Cash from Operations of 6388000.0 for Q1 2026, up 151.27% year-over-year from 2542263.21 in Q1 2025, and down 58.19% quarter-over-quarter from 15278000.0 in Q4 2025.
Amarin Corp Plcuk (AMRN) Cash from Operations (2010 - 2026) Analysis & Trends
Amarin Corp Plcuk (AMRN) has 17 years of Cash from Operations data on file, last reported at 6388000.0 in Q1 2026.
- Cash from Operations for Q1 2026 came in at 6388000.0, up 151.27% year-over-year; the trailing twelve-month figure through Mar 2026 was 25575000.0 (up 182.83% YoY), and the FY2025 annual result was 6728000.0, up 121.69% from the prior year.
- Cash from Operations eased to 6388000.0 in Q1 2026 per AMRN's latest filing, from 15278000.0 in the prior quarter.
- Over five years, Cash from Operations peaked at 16606000.0 in Q2 2025 and troughed at 98847000.0 in Q1 2022.
- A 5-year average of 11242117.65 and a median of 2749000.0 in 2024 frame the typical range for Cash from Operations.
- The sharpest annual moves came in 2024 and 2025: Cash from Operations sank 1963.57% in 2024, then soared 704.07% in 2025.
- A 5-year view of Cash from Operations shows it stood at 1552000.0 in 2022, then sank by 141.56% to 645000.0 in 2023, then slumped by 1963.57% to 13310000.0 in 2024, then jumped by 214.79% to 15278000.0 in 2025, then plunged by 58.19% to 6388000.0 in 2026.
- Business Quant data shows AMRN's Cash from Operations at 6388000.0 in Q1 2026, 15278000.0 in Q4 2025, and 12697000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. (Qtr) |
|---|---|---|---|---|---|
| 1 | Gsk | 92,316,836.42 Bn | 92,316,831.46 Bn | 7.76 Bn | 1.82 Bn |
| 2 | Eli Lilly | 983.57 Bn | 978.29 Bn | 16.22 Bn | 5.33 Bn |
| 3 | Johnson & Johnson | 553.56 Bn | 531.50 Bn | 15.96 Bn | 2.51 Bn |
| 4 | AbbVie | 383.35 Bn | 374.00 Bn | 10.78 Bn | 3.83 Bn |
| 5 | Merck | 281.71 Bn | 276.06 Bn | 12.09 Bn | 3.92 Bn |
| 6 | Amgen | 182.20 Bn | 170.16 Bn | 5.87 Bn | 2.19 Bn |
| 7 | Gilead Sciences | 153.71 Bn | 145.98 Bn | 5.52 Bn | 2.54 Bn |
| 8 | Pfizer | 143.75 Bn | 130.98 Bn | -1.21 Bn | 2.62 Bn |
| 9 | Bristol Myers Squibb | 109.71 Bn | 99.25 Bn | 8.07 Bn | 1.10 Bn |
| 10 | Amarin Corp Plcuk | 6.77 Bn | 6.59 Bn | 17.77 Mn | 6.39 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 6.39 Mn |
| Mar 31, 2026 | 6.39 Mn |
| Dec 31, 2025 | 15.28 Mn |
| Dec 31, 2025 | 15.28 Mn |
| Sep 30, 2025 | -12.70 Mn |
| Sep 30, 2025 | -12.70 Mn |
| Jun 30, 2025 | 16.61 Mn |
| Jun 30, 2025 | 16.61 Mn |
| Mar 31, 2025 | -12.46 Mn |
| Mar 31, 2025 | -12.46 Mn |
| Dec 31, 2024 | -13.31 Mn |
| Dec 31, 2024 | -13.31 Mn |
| Sep 30, 2024 | -2.36 Mn |
| Sep 30, 2024 | -2.36 Mn |
| Jun 30, 2024 | -2.75 Mn |
| Jun 30, 2024 | -2.75 Mn |
| Mar 31, 2024 | -12.60 Mn |
| Mar 31, 2024 | -12.60 Mn |
| Dec 31, 2023 | -645,000.00 |
| Dec 31, 2023 | -645,000.00 |